Thrombosis and Haemostasis, Table of Contents Thromb Haemost 2008; 99(06): 1127-1129DOI: 10.1160/TH08-01-0054 Letters to the Editor Schattauer GmbH Multiple electrode aggregometry and P2Y12 antagonists Authors Andrew Johnson Natalia Dovlatova Stan Heptinstall Recommend Article Abstract Buy Article(opens in new window) Full Text References References 1 Sibbing D, Braun S, Jawansky S. et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thomb Haemost 2008; 99: 121-126. 2 Tóth O, Calatzis A, Penz S. et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788. 3 Mueller T, Dieplinger B, Poelz W. et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer – comparison with two flow cytometric methods. Thromb Res 2007; 121: 249-258. 4 Seyfert UT, Haubelt H, Vogt A. et al. Variables influencing Multiplate™ whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007; 18: 199-206. 5 Mengistu AM, Wolf MW, Boldt J. et al. Evaluation of a new platelet function analyzer in cardiac surgery: a comparison of modified thromboelastography and whole-blood aggregometry. Cardiothorac Vasc Anesth 2008; 22: 40-46. 6 http://www.multiplate.net Accessed on January 26, 2008. 7 Dyszkiewicz-Korpanty A, Olteanu H, Frenkel EP. et al. Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the Platelet Function Analyzer (PFA-100™). Platelets 2007; 18: 491-46. 8 Perneby C, Wallén NH, Hofman-Bang C. et al. Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease. Thromb Haemost 2007; 98: 1316-1322. 9 Neubauer H, Lask S, Engelhardt A. et al. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 2008; 99: 357-362. 10 Steinhubl SR, Oh JJ, Oestreich JH. et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121: 527-534. 11 Fox SC, Behan MWH, Heptinstall S. Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium 2004; 35: 39-46. 12 http://www.themedicinescompany.com/prod ucts_cangrelor.shtml 13 Savi P, Pereillo JM, Uzabiaga MF. et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896. 14 Parikh SA, Beckman JA. Contemporary use of clopidogrel in patients with coronary artery disease. Curr Cardiol Rep 2007; 9: 257-263. 15 Williams ET, Jones KO, Ponsler GD. et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 2008 Mar 27 [E-pub ahead of print].. 16 Frelinger III AL, Jakubowski JA, Li Y. et al. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: influence of other blood cells, calcium, and aspirin. Thromb Haemost 2007; 98: 192-200.
